[1] Yang Wei, Yang Huasheng, Jiang Liangduo .,.Application of Relieving Exterior Syndrome in the treatment of Coronavirus Disease 2019 [J]. Journal of Shaanxi University of Traditional Chinese Medicine, 2020, (预出版): 54-60.
Application of Relieving Exterior Syndrome in the treatment of Coronavirus Disease 2019
- Keywords:
- Coronavirus Disease 2019; relieving exterior syndrome; diaphoresis; Guizhi Decoction; double solutionof exterior and interior
- Abstract:
- Based on the clinical practice of traditional Chinese medicine in the treatment of Coronavirus Disease 2019 ( COVID -19) , we think that the main syndromes of this disease are Wei and Qi phase syndrome. The main effective treatment in early stage is dispersing lung qi to penetrate pathogenic factors and relieve the external symptoms. The method of relieving exterior syndrome can be divided into several kinds depending on the composition or specific method of the drug, including pungent and wind, pungent and warm, strengthening the body to resolving the exterior, double solution of exterior and interior, removing dampness to relieving exterior syndrome and so on. Accurate syndrome differentiation and flexible modification is necessary in the treatment of COVID -19. Pay attention to details and contraindications of decoction is also necessary. Guizhi Decoction can be used as an experimental treatment when syndrome differentiation is not clear. The traditional Chinese medicine treatment of COVID -19 is mainly based on dispersing lung qi to penetrate pathogenic factors. This method should be used early to penetrate pathogens and pay attention to strengthening. It can not only improve the cure rate and also prevent the depression of positive deficiency caused by pathogenic factors , so then reduce the occurrence of critical illness.
References:
[1] Liu J, Liu Y, Xiang P, et al. Neutrophil - to – lymphocyte ratio predicts severe illness patients with 2019 novel coronavirus in the early stage[ EB/ OL] . ( 2020 - 02 - 12) [ 202002 - 26] . https: / / www. medrxiv. org/ content/10. 1101/ 2020. 02. 10. 20021584v1.
[2] Gorbalenya AE, Baker SC, Baric RS, et al. Severe acute respiratory syndrome - related coronavirus: the species and its viruses— a statement of the Coronavirus Study Group [ EB/ OL] . ( 2020 - 02 - 11) [ 2020 - 02 - 26] . https: / / www. biorxiv. org/ content/10. 1101/2020. 02.07. 937862v1.
[3〗Liu J, Zheng X, Tong Q, et al. Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS - CoV, MERSCoV, and 2019 - nCoV[ J/ OL] . J Med Virol, 2020( 202002 -13) [ 2020 - 02 - 26] . https: / / onlinelibrary. wiley.com/ doi/ full/10. 1002/ jmv. 25709.e
[4] Steimer DA, Hernandez O, Mason DP, et al. Timing of ECMO initiation impacts survival in influenza – associated ARDS[ J] . Thorac Cardiovasc Surg, 2019, 67 ( 3) : 212-215.
[5]金寿山.金寿山温病学讲稿[M].北京,人民卫生出版社,2008.
[6]杨华升,李丽,勾春燕,等.北京地区新型冠状病毒肺炎中医证候及病机特点初探.[J].北京中医药,(2020-02-13). http: / / kns. cnki. net/ kcms/ detail/11. 5635. r.20200212. 2218. 002. html.
[7]国家卫生健康委员会.关于印发新型冠状病毒感染的肺炎诊疗方案(试行第七版)的通知[ EB/ OL] . ( 2020-03 - 03) [ 2020 - 03 - 03] . http: / / www. nhc. gov. cn/yzygj/ s7653p/202001/
4294563ed35b43209b31739bd0785e67. shtml.
[8]周玉平,朱传新,万禧伟,等.咸宁地区3886例发热?咳嗽患者临床特征与实验室检查结果分析[J].检验医学与临床,( 2020 -03 -04) http: / / kns. cnki. net/ kcms/ detail/50. 1167. R. 20200304. 1246. 002. html.
[9]刘媛,胡秋红,黄柏学,等.从伏气温病探讨新型冠状病毒肺炎的“有病无症”[J].中医学报,(2020-03-03)http: / / kns. cnki. net/ kcms/ detail/41. 1411. R.20200302. 1833. 008. html.
Memo
基金项目:国家科技重大专项(2017ZX10305501);中医药防治2019-nCoV研究项目(2020YFC841500);国家中医药管理局第四批全国中医优秀人才研修项目(国中医药办人教函[2017]24)作者简介:杨华升,博士,主任医师,硕士生导师,第四批全国中医优秀人才?研究方向:中西医结合治疗肝病及传染病?E-mail:yangdoctor2000@qq.com.